Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

immunization

- PMLiVE

Moderna’s JN.1-adapted COVID-19 vaccine approved by MHRA for adults and children

The JCVI has already advised the UK government on eligible groups for this year’s autumn vaccination programme

- PMLiVE

Roche shares positive 48-week results for investigational BTK inhibitor in relapsing MS

Approximately 2.9 million people worldwide are affected by the neurological disease

- PMLiVE

PM Society’s sixth Careers Event on 26 February 2025

The event is focused on bringing industry experts from pharmaceutical companies and agencies together to advise on career opportunities

- PMLiVE

Novavax’s JN.1-adapted COVID-19 vaccine granted FDA emergency use authorisation

JN.1 only accounts for 0.2% of cases across the country but is the ‘parent strain’ of currently circulating variants

Bayer symbol

Bayer presents positive results for Kerendia in late-stage heart failure study

Approximately 55% of the 6.7 million heart failure patients in the US have an LVEF of at least 40%

- PMLiVE

Arrowhead’s RNAi therapeutic plozasiran shows promise in familial chylomicronaemia syndrome

There are currently no therapies in the US specifically approved to treat the rare genetic disorder

- PMLiVE

Hear From Her: Extraordinary Women Who Are Redefining Healthcare Leadership

That’s a wrap for Season 2 of Medscape Education’s Award-Winning Podcast Series, Hear From Her: Women in Healthcare Leadership! (Not to worry, Season 3 is just around the corner.)  And...

Medscape Education

- PMLiVE

Leading the way on the path to patient centricity

Find out how Mednet is leading the way to a truly patient-centric future for Pharma

Mednet

- PMLiVE

Bringing Clinicians Together for Oncology Education at ESMO 2024

ESMO 2024 comes with the debut of 2 new, exciting symposia hosted by the MedscapeLIVE! team. The symposia build on nearly 30 years of Medscape’s experience and excellence in both...

Medscape Education

- PMLiVE

Merck and Astellas/Pfizer’s bladder cancer combination granted EC approval

Bladder cancer is the fifth most commonly diagnosed cancer in Europe, with more than 165,000 annual cases

- PMLiVE

Sanofi’s investigational BTK inhibitor tolebrutinib shows promise in phase 3 MS study

The neurological disorder affects approximately 2.9 million people worldwide

- PMLiVE

Alnylam shares positive phase 3 results for vutrisiran in ATTR with cardiomyopathy

The company said it will be proceeding with regulatory filings for the therapy later this year

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links